A Phase 2 multi-center, randomized, double blind, placebo controlled, parallel group study to evaluate the efficacy and safety of T-817MA in patients with mild to moderate Alzheimers Disease (US202)
|Toyama Chemical Co., Ltd
|Male and Female Patients
|U.S. Govt. ID:
|Ruth Tejeda: 212-305-7661 / email@example.com
The purpose of this study is to determine whether an investigational drug, T-817MA, is safe and beneficial in delaying or altering the decline in memory and daily functioning when given to people with Alzheimer's disease. Participants will be given either an active study drug (T-817) or placebo (no active medication).
This study is closed
Karen Bell, MD
|Do you have mild to moderate Alzheimer's disease and are taking donepezil or rivastigmine transdermal (on skin) system?
|Are you living in an elderly community?
|Have you been diagnosed with any significant cardiac issues?